Microsoft Unveils Quine AI System to Accelerate Biological Research

Microsoft Research has unveiled Quine, a new artificial intelligence research system designed to help scientists explore biology across multiple levels, from genes and proteins to cells and tissues. Rather than functioning simply as a chatbot, Quine combines an AI world model of biology with tools for scientific reasoning, literature and computational analysis. Microsoft says the system is intended to help researchers generate hypotheses, predict the effects of biological interventions and determine which experiments are most worth pursuing.

A key feature of Quine is its ability to connect different types of biological information. The system is being trained across areas including genomics, proteins, chemistry, RNA and cell states, as well as biological imaging. Microsoft argues that learning these modalities together could allow evidence from one biological scale to inform predictions at another, potentially providing researchers with a more complete picture of how biological systems behave. The objective is not to replace laboratory experiments, but to use AI to narrow down promising possibilities before scientists commit time and expensive resources to physical testing.

Microsoft says Quine has already been tested in collaboration with researchers at the Broad Institute of MIT and Harvard. In one research effort, the system was used to prioritize compounds predicted to cause changes in tumour states, with several highly ranked candidates subsequently tested and validated across multiple laboratory assays. These results are still part of experimental research, and Microsoft emphasizes that Quine’s predictions can be incomplete or inaccurate and require review by qualified researchers and appropriate experimental validation.

The system is designed around a continuous feedback loop between AI and scientists. A researcher begins with a biological question, Quine can generate possible explanations or experimental proposals, and researchers then test selected ideas in the laboratory. The resulting experimental measurements can inform subsequent questions and research decisions. Microsoft hopes this approach will accelerate the traditionally slow cycle of proposing, testing and refining biological hypotheses, particularly in areas such as protein engineering, enzyme discovery and early-stage therapeutic research.

For now, Quine remains an experimental research technology rather than a commercial medical system. Microsoft is opening access to a limited group of researchers through its Quine Fellows programme to determine where the system can genuinely accelerate scientific discovery and where it still falls short. The company says the long-term goal is to expand access through products such as Microsoft Discovery. If the approach proves reliable, Quine could represent a significant step toward AI systems that do more than answer scientific questions and instead participate in an iterative process of computational prediction, experimentation and discovery.